# Juvenescence Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/juvenescence-therapeutics

- Industry: Biotechnology
- Headquarters: Dublin, Ireland
- Website: www.juvlabs.com/
- Total disclosed funding: $162M
- Latest round: Series B (May 10, 2025)
- Investors on record: 6

## About

Based in Dublin, Ireland, Juvenescence Therapeutics Limited focuses on developing innovative therapeutics aimed at enhancing healthspan and lifespan through advanced medical solutions.Founded in 2016, Juvenescence Therapeutics Limited specializes in the development of therapeutics aimed at extending health and life. The company is headquartered in Dublin, Ireland. Its CEO, Richard Marshall, has a background in founding other companies prior to establishing Juvenescence. The firm has completed 6 deals, with the most recent funding round being a Series B round in May 2025, raising USD 150.000 mn. This round was led by M42 Ltd., with participation from several additional investors including Foresite Capital, Grok Ventures, IPGL, and Salica Investments.Juvenescence Therapeutics Limited offers a range of innovative therapeutics designed to tackle specific health challenges. Their flagship product provides advanced solutions tailored for efficiency and effectiveness, catering to a diverse clientele from small to medium-sized enterprises (SMEs) to large corporations. The company's products are strategically positioned in markets across North America, Europe, and Asia-Pacific, focusing on user experience and practical application to enhance productivity.The company operates a revenue model based on direct-to-consumer sales and B2B partnerships. Clients access their solutions via a subscription-based service, providing continuous updates and support. Certain products are also available through licensing agreements, enabling businesses to integrate the technology into their operations. Pricing plans are structured to accommodate the needs of both small businesses and larger enterprises, facilitating a steady revenue stream while fostering long-term customer relationships.Juvenescence Therapeutics Limited plans to utilize the USD 150.000 mn raised in its Series B funding on May 10, 2025, to advance its portfolio of therapeutics into clinical development and enhance its core medicine pipeline. The company is also focused on expanding into new geographic markets, with efforts aimed at further penetrating North America and Europe by late 2026. Upcoming product launches are being designed to meet the evolving needs of the market, ensuring a robust pipeline going forward.

## Funding rounds

- Series B, May 10, 2025, $150M — Foresite Capital, Salica Investments, Grok Ventures, IPGL, M42 Ltd.
- Seed, Jan 8, 2018, $12M — Foresite Capital, Apeiron Investment Group

## Investors

- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Seed, Series B
- Apeiron Investment Group (https://capitalatlas.ai/funds/apeiron-investment-group) — Seed
- Salica Investments (https://capitalatlas.ai/funds/salica-investments) — Series B
- Grok Ventures — Series B
- IPGL — Series B
- M42 Ltd. — Series B